Genedrive PLC NICE to evaluate the Genedrive(R) MT-RNR1 Test (0121P)
16 June 2022 - 4:00PM
UK Regulatory
TIDMGDR
RNS Number : 0121P
Genedrive PLC
16 June 2022
genedrive plc
("genedrive" or the "Company")
NICE to evaluate the Genedrive (R) MT-RNR1 Test under their
Diagnostics Assessment Programme
genedrive plc (AIM: GDR), the near patient molecular diagnostics
company, announces that the UK's National Institute for Health and
Clinical Excellence ('NICE') has started an evaluation of the
Genedrive(R) MT-RNR1 test via their Diagnostics Assessment
Programme ('DAP'). DAP evaluations are designed to provide robust
recommendations on the use of new products, which is presented in
the form of NICE guidance, and to promote rapid and consistent
adoption of clinically innovative and cost-effective diagnostic
technologies in the NHS.
An independent advisory committee considers the evidence
provided, makes draft recommendations for public consultation and
ultimately makes final recommendations for publication in NICE
guidance. The guidance produced is used by NHS commissioners,
practitioners, healthcare operational managers and purchasing and
procurement organisations .
genedrive's assay is the world's first rapid point of care test
to screen infants in an urgent care setting for a genetic variant
that will cause life-long hearing loss when carriers of the variant
are given certain antibiotics. Those that carry the variant can
then be given alternative treatments following detection of the
variant by the Genedrive(R) MT-RNR1 test.
David Budd, CEO of genedrive plc, said: "We are grateful to NICE
for their engagement and interest in our innovative technology and
pleased that the Genedrive(R) MT-RNR1 test was selected for this
programme following successful publication of the NICE Medtech
innovation briefing ("MIB290") in March. The NICE guidance is an
important element required to drive uptake and adoption of the test
in the NHS by demonstrating the cost-saving efficiencies. The
application of Genedrive's technology shows how a rapid,
affordable, point-of-care test could impact patients' treatment and
quality of life."
For further details please contact:
genedrive plc +44 (0)161 989 0245
David Budd: CEO / Russ Shaw: CFO
Peel Hunt LLP (Nominated Adviser
and Joint Broker) +44 (0)20 7418 8900
James Steel
finnCap (Joint Broker) +44 (0)20 7220 0500
Geoff Nash / Kate Bannatyne / Alice
Lane
Walbrook PR Ltd (Media & Investor +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Relations)
+44 (0)7980 541 893 / +44 (0)7876
Paul McManus / Anna Dunphy 741 001
About genedrive plc ( http://www.genedriveplc.com ) genedrive
plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need molecular diagnostics platform for the
diagnosis of infectious diseases and for use in patient
stratification (genotyping), pathogen detection and other
indications. The Company has assays on market for the detection of
MT-RNR1, HCV, certain military biological targets, and a high
throughput SARS-CoV-2 assay. The Company recently released a point
of care test for Covid-19.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGPUBUQUPPGWA
(END) Dow Jones Newswires
June 16, 2022 02:00 ET (06:00 GMT)
Genedrive (LSE:GDR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2023 to Apr 2024